Last reviewed · How we verify
A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors
This study is looking at how Mim8 works compared to other medicines in children with haemophilia A, who either have inhibitors or do not have inhibitors. Mim8 is a new medicine that will be used for prevention of bleeds. Mim8 will be injected with a thin needle into the skin. The study will last for about 54-98 weeks, from screening to follow-up visit, In case the participant experiences bleeds, these can be treated with additional haemostatic medicine as agreed with the study doctor.
Details
| Lead sponsor | Novo Nordisk A/S |
|---|---|
| Phase | PHASE3 |
| Status | COMPLETED |
| Enrolment | 70 |
| Start date | Mon Apr 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Wed Nov 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Haemophilia A With or Without Inhibitors
Interventions
- Mim8
Countries
Italy, Japan, Taiwan, Poland, South Korea, Netherlands, Russia, Lithuania, Portugal, United States, South Africa, Israel, Canada, Spain, United Kingdom, Germany, Switzerland, China, India